Detalhe da pesquisa
1.
Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes.
Diabetologia
; 57(9): 1977-85, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24957662
2.
Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model.
Metabolites
; 11(7)2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34203471
3.
Stably engineered nanobubbles and ultrasound - An effective platform for enhanced macromolecular delivery to representative cells of the retina.
PLoS One
; 12(5): e0178305, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28542473
4.
Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.
Sci Rep
; 7(1): 15190, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29123192
5.
Tapping into Mitochondria to Find Novel Targets for Diabetes Complications.
Curr Drug Targets
; 17(12): 1341-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26212267
6.
Real-time quantification of oxidative stress and the protective effect of nitroxide antioxidants.
Neurochem Int
; 92: 1-12, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26592979
7.
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Sci Rep
; 6: 26428, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27226136
8.
Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease.
Curr Opin Pharmacol
; 13(4): 654-61, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23871446
9.
Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Sci Rep
; 6: 28124, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27389496